Atlas AI: Drug Discovery at the Speed of AI (Presented by Deloitte)

In an era when the costs and timelines of pharmaceutical R&D have escalated — now exceeding $2 billion and requiring upwards of a decade to bring an average new drug to market — the industry confronts substantial obstacles. These challenges range from isolated data repositories and incompatible analytical pipelines to the protracted periods required for human-centric manual analysis. Addressing these pressing issues, we introduce Atlas AI, a revolutionary product developed through a strategic partnership between NVIDIA and Deloitte. Leveraging state-of-the-art NVIDIA GPUs and software such as BioNeMo, NeMo large language models, and the DGX Cloud, Atlas AI embodies a scientific data-centric and AI-first methodology to fundamentally transform the drug discovery landscape. It facilitates seamless integration of both proprietary and open-source life sciences research data, breaking down data silos that hamper cohesive analysis.